Metabolism & Elimination Both peptides undergo similar metabolic pathways despite their structural differences: GLP1 metabolism: Proteolytic cleavage of the peptide backbone across multiple tissues Sequential beta-oxidation of the fatty acid side chain No organ-specific metabolism with degradation occurring in multiple tissues simultaneously Six identified metabolites in human plasma, with metabolite P3 comprising approximately 7.7% of circulating drug-related material Intact peptide predominance with 69-83% of circulating material remaining as intact GLP1 Cagrilintide metabolism: Similar proteolytic pathways to GLP1 due to peptide structure Fatty acid chain processing through beta-oxidation mechanisms Albumin-mediated protection reducing enzymatic access to the peptide backbone Reversible albumin binding allowing gradual release and metabolism No specific organ predominance for metabolic clearance The remarkably similar half-lives of both peptides (159-195 hours for cagrilintide, 145-165 hours for GLP1) enable synchronized pharmacokinetic profiles ideal for fixed-dose combination therapy

BPC-157 is often researched for its potential ability to support tissue healing, joint recovery, and inflammation response
It provides broad-spectrum SPF50+ PA++++ protection against UVA and UVB rays, with a gentle toning effect that helps even out skin tone, conceal dullness, and give an instant, natural-looking radiance
Hum Cell (2020) 33(4):108190
The copper(II) ion is coordinated by the glycine amino terminus, the deprotonated glycine to histidine peptide-bond nitrogen, and the histidine imidazole nitrogen, giving the complex its characteristic colour and stability